Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) EPS (Weighted Average and Diluted) (2023 - 2025)

Mangoceuticals' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.56 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 43.43% year-over-year to -$0.56; the TTM value through Sep 2025 reached -$2.72, up 74.6%, while the annual FY2024 figure was -$4.84, 43.59% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.56 at Mangoceuticals, down from -$0.31 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.09 in Q2 2024 and bottomed at -$8.13 in Q4 2023.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.56 (2025), against an average of -$1.41.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 93.11% in 2024 against a maximum downside of 559.45% in 2024.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$8.13 in 2023, then skyrocketed by 93.11% to -$0.56 in 2024, then fell by 0.0% to -$0.56 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's EPS (Weighted Average and Diluted) are -$0.56 (Q3 2025), -$0.31 (Q2 2025), and -$1.29 (Q1 2025).